



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, February 17, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Karen Gunning, PharmD.

Raymond Ward, M.D.

Michael Flynn, M.D.

Kort DeLost, R.Ph.

Brandon Jennings, PharmD.

Lisa Hulbert R.Ph.

Beth Johnson, R.Ph.

Committee Members Excused:

Ellie Brownstein, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD.

Richard Sorenson, R.N.

Jennifer Zeleny, CPhT, MPH

University of Utah Drug Information Center Staff Present:

Gary Oderda, PharmD.

Other Individuals Present:

Brett Brewer, EMD Serono

Brian Streng, GSK

Vern Stacey, GSK

Brad Bywather, Elan

Meeting conducted by: Karen Gunning PharmD., Co-Chairperson.

-
1. Review and Approval of Minutes: Dr. Ward moved to approve the minutes. Kort DeLost clarified that when he was talking about MAC's on oral contraceptives he meant that a separate MAC should be determined for each line on the table that was presented in the last meeting. He then seconded the motion to approve the minutes with that clarifying statement. The motion passed with unanimous votes by Kort DeLost, Brandon Jennings, Beth Johnson, Karen Gunning, Lisa Hulbert, and Dr. Ward.
 2. DUR Board Update: Robyn Seely addressed the Committee. Last week the DUR Board met and placed Pradaxa and Butrans under Prior Authorization. Next month, the Board will consider oral Multiple Sclerosis therapies and new indications for Vivitrol.
 3. Drugs for BPH: Dr. Gary Oderda presented the P&T Committee with research done on the 5-Alpha Reductase Inhibitors and Alpha-1 Adrenergic Blockers.

Brian Streng of GSK addressed the Committee in favor of the benefits of Jalyn.

Karen Gunning asked if the 5-Alpha Reductase Inhibitors are limited to payment for men only in the claims system. Jennifer stated that she did not know, but would look into that.

Dr. Ward moved that the 5-Alpha Reductase Inhibitors are equally safe and efficacious and Medicaid may choose preferred drugs based on cost. Dr. Flynn seconded the motion. The motion passed with unanimous votes by Kort DeLost, Brandon Jennings, Beth Johnson, Karen Gunning, Lisa Hulbert, Dr. Flynn, and Dr. Ward.

Karen Gunning stated that she believed there was a large utilization of prazosin in the psychiatric community for PTSD. She had read studies on the use of prazosin for that purpose, and believed that the high utilization of that agent could be attributed to that indication.

The Committee felt that it was also important to maintain access to tamsulosin because it does not have an effect on blood pressure. Additionally, terazosin and doxazosin do have additional indications for blood pressure, and should be kept available for that purpose.

Dr. Ward moved that doxazosin, terazosin, prazosin, and tamsulosin should be included on the PDL. Other agents may be included if they are cost-favorable. Dr. Flynn seconded the motion. The motion passed with unanimous votes by Kort DeLost, Brandon Jennings, Beth Johnson, Karen Gunning, Lisa Hulbert, Dr. Flynn, and Dr. Ward.

The Committee discussed Jalyn. Beth Johnson felt that it would be important to include based on compliance. Additional copays may make a client less likely to fill a prescription, and decrease compliance. Dr. Flynn disagreed in this case, because symptoms of BPH are bothersome. Based on symptoms, a client would be likely to remain compliant with medications for this particular disease state.

Dr. Flynn did not make a specific motion to include or exclude Jalyn. He stated that based on Committee deliberations, Medicaid knows that it may be included or excluded based on cost.

Next Meeting Set for Thursday, March 17, 2011

Meeting Adjourned.

Minutes prepared by Jennifer Zeleny